Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection
Source: Clinical Microbiology & Infection, Volume 10, Number 4, April 2004 , pp. 337-339(3)
Kidney recipients (n = 51) at risk of cytomegalovirus (CMV) disease, and requiring anti-lymphocyte globulin therapy because of biopsy-proven rejection, received high-dose ganciclovir, three times a week, for a total of nine doses. CMV disease was observed in seven (14%) patients within 6 months. Six of these patients were in a group of 45 CMV-seropositive recipients, and one was in a high-risk group of CMV-seronegative recipients. High-dose intravenous ganciclovir, three times a week, seems to be an efficient, safe and easy way to prevent CMV disease in patients treated with anti-lymphocyte globulins for acute rejection.
Document Type: Research Article
Affiliations: 1: Nephrology 2: Institute for Pathology, University Hospital, CH-4410 Liestal 3: Hôpital Régional, CH-2900 Porrentruy, Switzerland 4: Pneumology, Department of Internal Medicine, University Hospital, CH-4031 Basel
Publication date: April 2004